View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
April 24, 2019updated 12 Jul 2022 1:06pm

IQVIA releases new report on trial productivity trends

IQVIA Institute for Human Data Science has reported findings from a new study that analyses past and future clinical trial productivity trends.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Titled ‘The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity’, the new report is based on information from IQVIA databases and/or third-parties.

It examines trial productivity trends using the firm’s Clinical Development Productivity Index, which is designed to reflect changes in trial complexity, success and timeframe.

According to the study, trial productivity during the coming five years will be primarily influenced by key trends such as biomarkers use, pre-screened patient pools, regulatory shifts and artificial intelligence and predictive analytics.

IQVIA Institute for Human Data Science executive director Murray Aitken said: “As advances in science, technology and data gradually find application within clinical development, the length of time that trials take to complete, the resources required due to trial complexity and likelihood of trial success are all shifting, with impacts varying by therapy area.”

The company identified multiple trends that would drive clinical development at therapy-area level.

Digital health technologies are set to allow remote collection of clinical data, and thus facilitate virtual trials, while patient-reported outcomes are expected to provide information on drug use outside clinical setting and speed-up trial durations.

IQVIA noted that real-world data would help optimise trial design and accelerate investigator and site selection. It could also aid in new trial designs through virtual control arms.

In addition, predictive analytics and artificial intelligence are expected to enable identification of new clinical hypotheses, cut trial design risks and speed-up enrolment via detection of appropriate patients.

The report further noted that changes in types of drugs assessed, such as targeted treatments, have fast-tracked development timelines but involve longer follow-up durations.

Use of biomarkers to identify patients who are more likely to respond is said to have led to improvements in efficacy, safety and success.

Moreover, trial productivity is being influenced by regulatory system changes and pre-screened patient pools and direct-to-patient recruitment.

Also, the study revealed increased investment in research and development last year.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena